Immunological evaluation of the application of experimental vaccines “Repro-Sui-Vac-P” in industrial pig breeding

Abstract

The article presents data on the optimization of the clinical protocol for the use of oil and adsorbed forms of experimental vaccine “ReproSuiVac-P” in industrial pig breeding (in the nucleus of herd, in groups of growing and fattening) in the system of biosafety measures “StopASFmix” based on immunological indicators of immunity, including humoral and cellular, with regards of the average daily growth of piglets) and specific (dynamics of postvaccinal antibodies, the intensity of population immunity, the resistance of vaccinated pigs relative to carrier-status of Mannheimia haemolytica). The obtained results allowed, at the level of probability not less than p≤0.01 (n = 879 pigs of different technological groups), to develop a technological card of vaccinations, which provides application of: a) oil form “ReproSuiVac-P” with bacterin on boars, lactating and barren sows twice with an interval 3 weeks in doses of 5+5 sm3; b) oil form of the vaccine in the group of weaned piglets 32nd–35th days of age at a single dose of 1–2 sm3; c) adsorbed with toxoid form of vaccine to sows of the second trimester of gestation twice with an interval of 2 weeks in doses of 5+7 sm3. Based on the indicators of constitutional and specific post-vaccination immunity against associated circovirus-pasteurellosis infection, a technological card of application of experimental vaccine “ReproSuiVac-P” in the main herd and in rearing groups of the industrial pig breeding was developed